Anirudha Dasgupta, MD
Hematology & Oncology · Kingwood, TXNPI 1841298387
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 28.2% of the total. Reporting peaked in 2024 at $17,737 and has fallen 77.3% since, to $4,032 in 2025.
Across 1,164 payments — averaging $41.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$14K
- AstraZeneca$5K
- Pfizer$3K
- Array Biopharma Inc$2K
- Morphosys, US Inc.$2K
- Exelixis Inc.$2K
- plus $20K from 54 others
Across 224 payments — averaging $32,737 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4.2M
- Merck$1.4M
- Astrazeneca UK Limited$954K
- Eli Lilly$334K
- Biontech SE$271K
- E.r. Squibb & Sons, L.L.C.$85K
- plus $106K from 7 others
What the payments were for
- Consulting fees$5,15511%
- Speaking & faculty fees$5,39011%
- Travel & lodging$13,82429%
- Food & beverage$23,05248%
- Education$7892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,210 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 17 | $397,137 |
| RevlimidLenalidomide | 26 | $373,619 |
| JakafiRuxolitinib Phosphate | 19 | $315,273 |
| PomalystPomalidomide | 12 | $277,260 |
| ImbruvicaIbrutinib | 13 | $198,069 |
| BrukinsaZanubrutinib | 12 | $188,029 |
| CalquenceAcalabrutinib Maleate | 12 | $185,023 |
| EliquisApixaban | 201 | $147,159 |
| Somatuline DepotLanreotide Acetate | 12 | $120,599 |
| Lenalidomide | 11 | $87,120 |
| XareltoRivaroxaban | 74 | $56,459 |
| Megestrol Acetate | 35 | $3,546 |
| Fentanyl | 33 | $3,542 |
| Deferasirox | 13 | $3,271 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 102 | $3,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $737 | $397,13717 claims |
| Bristol Myers SquibbRevlimid | $979 | $373,61926 claims |
| Incyte CorporationJakafi | $432 | $315,27319 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,400 | $277,26012 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $159 | $198,06913 claims |
| Beigene USA, Inc.Brukinsa | $254 | $188,02912 claims |
| AstraZenecaCalquence | $5,433 | $185,02312 claims |
| PfizerEliquis | $3,096 | $147,159201 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $163 | $120,59912 claims |
| Johnson & JohnsonXarelto | $649 | $56,45974 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Kingwood
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.